
For the first time since the insulin market stagnated due to price pressure in the US – forcing Novo Nordisk to book a notorious downgrade in 2016 – the most talked-about drug in Novo Nordisk's diabetes pipeline is once again an insulin.
The drug bears the name insulin icodec and passed its phase 2 studies in June. The drug is special in the sense that patients need only take it once a week rather than one or more times every day.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app